MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
17.53
+0.29 (+1.68%)
At close: 4:00PM EST

17.53 0.00 (0.00%)
After hours: 6:46PM EST

Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous close17.24
Open17.50
Bid17.52 x 4000
Ask17.89 x 4000
Day's range17.17 - 17.77
52-week range16.63 - 36.46
Volume8,394,090
Avg. volume5,763,401
Market cap9.048B
Beta (3Y monthly)1.76
PE ratio (TTM)194.78
EPS (TTM)0.09
Earnings date5 Nov 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend date2007-06-27
1y target est25.81
  • Business Wire

    Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

    Mylan N.V. (MYL) and Pfizer Inc. (PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs). Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide. “The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced.

  • Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase
    Zacks

    Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

    Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

  • Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates
    Zacks

    Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

    Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

  • Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates
    Zacks

    Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates

    Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.

  • Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss
    Zacks

    Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss

    Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.

  • Mylan (MYL) Q3 Earnings Surpass Estimates
    Zacks

    Mylan (MYL) Q3 Earnings Surpass Estimates

    Mylan (MYL) delivered earnings and revenue surprises of 2.63% and -2.39%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Mylan shares slide after warning of hit to revenue
    Reuters

    Mylan shares slide after warning of hit to revenue

    Mylan, which posted higher-than-expected third-quarter profit with the help of cost constraints, said it would reassess products it sells outside United States and had nearly completed its review of U.S. products. The review process should not affect net profit, President Rajiv Malik said on a conference call with analysts. Mylan in July agreed to merge with Pfizer Inc's Upjohn unit that sells off-patent branded drugs.

  • Mylan Earnings Beat, Revenue Misses In Q3
    Investing.com

    Mylan Earnings Beat, Revenue Misses In Q3

    Investing.com - Mylan reported third quarter earnings that beat analysts' expectations on Tuesday and revenue that fell short of forecasts.

  • Investing.com

    Day Ahead: Top 3 Things to Watch

    Investing.com - Here's a preview of the top 3 things that could rock markets tomorrow.

  • Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
    Zacks

    Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

    Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

  • Should You Buy Mylan (MYL) Ahead of Earnings?
    Zacks

    Should You Buy Mylan (MYL) Ahead of Earnings?

    Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View
    Zacks

    Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View

    Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

  • Mylan (MYL) to Report Q3 Earnings: What's in the Offing?
    Zacks

    Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

    Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.

  • Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?

    Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View
    Zacks

    Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View

    Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.

  • Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?
    Zacks

    Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?

    During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

  • Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
    Zacks

    Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

    While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.

  • Why the Earnings Surprise Streak Could Continue for Mylan (MYL)
    Zacks

    Why the Earnings Surprise Streak Could Continue for Mylan (MYL)

    Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Theravance Pipeline Strong, Dependence on Yupelri a Concern
    Zacks

    Theravance Pipeline Strong, Dependence on Yupelri a Concern

    Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.

  • Reuters - UK Focus

    UPDATE 1-U.S. Supreme Court rejects Acorda appeal in MS drug patent fight

    The U.S. Supreme Court on Monday declined to hear Acorda Therapeutics Inc's appeal of a lower court ruling that allowed generic versions of its multiple sclerosis treatment Ampyra and caused the drug's sales to plummet. The justices refused to review a September 2018 decision by the U.S. Court of Appeals for the Federal Circuit to cancel Acorda's patents covering Ampyra, a ruling the Ardsley, New York-based company and the pharmaceutical industry portrayed as a threat to innovation and bad for patients. According to Acorda, Ampyra was the first drug approved to improve walking in people with multiple sclerosis, an incurable and potentially disabling disease of the brain and spinal cord that can lead to symptoms including pain, visual impairments and difficulty walking.

  • Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
    Zacks

    Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

    Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

  • Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe
    Reuters

    Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe

    The SEC on Friday said Mylan kept investors in the dark when it failed to disclose or set aside money for the two-year probe by the U.S. Department of Justice, prior to announcing a $465 million settlement in October 2016. In a statement, Mylan called the SEC civil settlement "the right course of action," and said it was committed to the "highest levels of integrity" when communicating with investors and making disclosures in public filings.

  • Reuters - UK Focus

    UPDATE 2-Mylan to pay $30 mln U.S. SEC fine related to EpiPen overcharge probe

    Mylan NV has agreed to pay a $30 million fine to settle U.S. Securities and Exchange Commission charges it hid from investors the impact of a federal probe into the drugmaker's overbilling the government for its EpiPen allergy treatment. The SEC on Friday said Mylan kept investors in the dark when it failed to disclose or set aside money for the two-year probe by the U.S. Department of Justice, prior to announcing a $465 million settlement in October 2016. In a statement, Mylan called the SEC civil settlement "the right course of action," and said it was committed to the "highest levels of integrity" when communicating with investors and making disclosures in public filings.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more